IL-1 beta oligonucleotide antisense therapy (SNA) (Exicure)

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug NameIL-1 beta oligonucleotide antisense therapy (SNA) (Exicure)
Drug Alias NameIL-1 beta spherical nucleic acids (Exicure)
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense
Mechanisms of ActionInterleukin-1 beta inhibitors
TargetsInterleukin-1 beta
Therapy Area/IndicationsEpidermolysis Bullosa
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesExicure Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesExicure Inc
Active IndicationsN/A
Inactive IndicationsEpidermolysis Bullosa

Other Information

ATC CodeN/A
Related LinksN/A